What question did this study set out to answer?

August 13, 2026PathophysiologyOpen Access

A Comprehensive Meta-Analysis of the Cardiovascular Adverse Effects of Bispecific Antibody Therapy in Hematologic Malignancies

View Full Paper

Ask AI

Bookmark

Authors

Meta-analysis investigates cardiovascular risks of bispecific antibodies in hematologic malignancies, indicating a need for careful monitoring.

This analysis aims to evaluate the cardiovascular adverse effects of bispecific antibody therapies in patients with hematologic malignancies.
Conducted a systematic literature review identifying seven bispecific antibodies across 25 clinical trials (Phase I–III).
Analyzed data for adverse cardiovascular events like arrhythmias and heart failure using random-effects model.
Calculated proportions and 95% confidence intervals for event rates.
Pooled analysis shows 13.6% cardiac arrhythmia (95% CI 10.1–18.2%, p = 0.05).
Significant hypotension observed at 13.3% (95% CI 10–17.3%, p < 0.0001).
Tachycardia occurred in 10.2% of patients (95% CI 7.6–13.5%, p = 0.0003).

Tai et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark

Meta-analysis investigates cardiovascular risks of bispecific antibodies in hematologic malignancies, indicating a need for careful monitoring.